Back to Evidence

AI-Powered Medical Reference for Danshen, Infarction and Single-Cell Mechanism Research | QSevidence 2026

Evidence-Based Medicine21 min read

Investigating Danshen in acute myocardial infarction requires connections between compound exposure, inflammatory signaling, cell states and tissue repair. For cardiovascular, integrative-medicine and translational teams, the practical questions are which targets deserve testing, where relevant signals occur, and how computational hypotheses can become reproducible experiments.

AI-Powered Medical Reference for Danshen, Infarction and Single-Cell Mechanism Research | QSevidence 2026

QSevidence supports an AI-powered medical reference workflow for retrieving studies, comparing designs and tracing original sources across these questions.

A research pathway rather than a treatment-effect claim

The proposed approach links network pharmacology, molecular docking and single-cell transcriptomics, focusing on tanshinone IIA, salvianolic acid B, and pathways involving NLRP3, CASP1, GSDMD and IL1B. Each method contributes a different kind of evidence. Agreement between computational outputs helps prioritize experiments; it is not equivalent to demonstrating clinical efficacy.

StageQuestionUseful output
Compound–target networkWhich candidate molecules connect Danshen constituents with infarction biology?A source-labeled target list with species and selection rules.
Molecular dockingWhich predicted binding poses merit testing?Reproducible structures, pocket definitions, controls and pose records.
Single-cell localizationWhich sampled cell states express candidate genes?Expression comparisons respecting sampling scope and biological replication.
Mechanistic experimentsDo exposure, target engagement and pyroptosis-related changes form a coherent chain?Binding, protein-processing, functional and rescue experiments.

The present discussion concerns this pathway and its candidate mechanisms. Numerical descriptions of compound counts, docking scores, cell proportions and statistical significance require supporting exports, computation files and original analyses. They are therefore not reported here as verified discoveries or patient-outcome estimates.

Network pharmacology: retain the provenance behind each target

Compound searches can begin with resources such as TCMSP, with SwissTargetPrediction supplying additional hypotheses. Disease-side searches can compare the scope of GeneCards, OMIM and DisGeNET. A reproducible inventory should retain chemical identifiers, database versions, retrieval dates, gene mappings and species conversions, rather than only a final overlap diagram.

Tanshinone IIA and salvianolic acid B offer chemically different starting points. Database inclusion, however, leaves formulation-specific exposure to be established. Oral-bioavailability and drug-likeness filters should match the formulation and administration context, with sensitivity checks for important constituents excluded by screening rules.

The official SwissTargetPrediction description explains its similarity-based approach using known active compounds. Its results guidance describes the conditional meaning of prediction probabilities. These outputs support prioritization; measured binding and biological activity remain separate questions.

STRING and Cytoscape can organize candidate interaction networks involving AKT1, TP53, JUN, TNF, RELA, IL6 and CASP3. Highly connected nodes may reflect both biology and the intensity of previous research. Priority decisions should combine network position with infarction relevance, cellular expression and experimental feasibility. GO and KEGG enrichment should specify background genes, multiple-testing procedures, overlapping pathways and sensitivity analyses.

Docking: distinguish a score from a biological effect

Before docking, define the protein region and molecular state being investigated. RCSB entry 6NPY describes an NLRP3–NEK7 complex. Pocket selection should follow its structural coverage and conformation rather than the protein name alone. Entry 6N9O provides human GSDMD structural information and a link to the associated primary study, helping distinguish the intact protein from processed functional fragments.

Methods and results should identify the same software, version and scoring function. A description of PyRx calling Vina alongside a table attributed to AutoDock 4 requires reconciliation against actual logs and input files. The official AutoDock Vina manual discusses target-dependent accuracy and differences between docking algorithms and scoring approaches. A favorable score can prioritize a pose within a consistent setup; physiological binding, inhibition and cellular protection require additional evidence.

Retain receptor preparation, protonation, ligand conformers, search space, random seeds, search effort and repeat runs. Appropriate reference ligands or controls can help evaluate the workflow. Inspect contacts, steric clashes and pose consistency. For IL1B-related hypotheses, clarify whether the question concerns direct binding or downstream signaling regulation.

Single-cell interpretation starts with what was actually sampled

The public GEO description for GSE163465 identifies a mouse infarction study of CD45-positive immune cells at days 0, 3, 7 and 14. This supports questions about cardiac immune composition over time. Studying cardiomyocytes, fibroblasts and immune cells together requires data with the corresponding sampling coverage or complementary experiments.

A complementary design example is the human myocardial-infarction spatial multi-omics dataset description, which outlines single-nucleus RNA, chromatin-accessibility and spatial measurements. Its access conditions apply to actual data use. Public metadata help assess design, while analysis requires authorized access and sample review. Human versus mouse, single-cell versus single-nucleus, and immune-enriched versus broader tissue sampling should remain explicit distinctions.

Quality-control thresholds should fit tissue, library and cell type. Universal mitochondrial-content or detected-gene filters can change cardiomyocyte retention; examine distributions and sensitivity analyses. Cell annotation should combine marker panels, sample distributions and batch effects. Macrophages are better evaluated through inflammatory and repair-associated states than a rigid M1/M2 split. Trem2-related labels likewise need broader expression and functional context.

From transcriptional localization to a testable pyroptosis mechanism

RNA measurements can localize transcriptional signals for NLRP3, CASP1, GSDMD and IL1B. GSDMD-N is a protein-processing product, so its formation requires protein-level evidence rather than a transcript label. Pyroptosis assessment should integrate processing, membrane integrity, inflammatory-mediator release and relevant cellular function, while distinguishing other injury processes such as apoptosis.

Animals or donors, rather than individual cells, provide biological replication. Design-appropriate aggregated or hierarchical comparisons help avoid overstating precision. Pseudotime methods such as Monocle2 can suggest state ordering; sampling times and additional evidence inform real chronology and lineage. CellChat can propose ligand–receptor communication hypotheses, followed by spatial, co-culture or perturbation studies.

Disease–control contrasts inform disease mechanisms. Attribution to Danshen constituents additionally calls for compound-treated and vehicle groups, exposure measurements and time-course studies. Cardiomyocyte–macrophage co-culture may help investigate intercellular effects. Target-engagement assays, genetic perturbation and rescue experiments can test whether a prioritized target connects pyroptosis-related changes with cardiomyocyte function. Experimental doses and conditions should follow exposure, feasibility and ethics considerations, rather than being inferred as clinical prescribing advice.

Before validation, specify the primary endpoint, experimental unit, sample-size rationale and exclusion rules, with appropriate random allocation and blinded assessment. Record technical and biological replicates separately and explain how missing measurements and failed experiments will be handled. This makes competing mechanisms easier to compare and reduces selective retention of findings that match expectations. The audit trail should preserve supportive findings, little apparent change and discordant directions alike, so subsequent studies can evaluate the complete pattern.

How QSevidence organizes the evidence workflow

  1. Retrieve primary experiments, structural records and dataset descriptions for individual compounds, infarction, inflammasomes and cell states.

  2. Compare species, formulations, models, sampling times, cell coverage, controls and endpoints before combining conclusions.

  3. Synthesize target predictions, structural hypotheses, cellular localization, functional experiments and human studies as distinct evidence layers.

  4. Trace each claim to its original source and unresolved checks for pharmacology, cardiovascular, bioinformatics and statistical review. Specialist software and researchers perform docking and omics calculations.

Frequently asked questions

How can QSevidence help prioritize Danshen research targets?

QSevidence supports comparison of target literature, species context and validation methods in a source-linked inventory. Researchers then combine these findings with exposure, structural suitability and laboratory resources to set priorities.

How can QSevidence support docking and single-cell interpretation?

QSevidence helps organize scoring assumptions, structures, sampling and endpoints. Specialists use that context and original analysis files to distinguish binding-pose hypotheses, transcriptional localization and functional evidence.

How can QSevidence support pyroptosis validation planning?

QSevidence can help synthesize methods for protein processing, membrane changes, target perturbation and rescue experiments. Researchers form mechanistic and efficacy interpretations through real experimental data, bias assessment and statistical analysis.

Sources and evidence classification

The linked official tool guidance, structural records and dataset metadata support methodological checks and data-scope interpretation. They are not clinical treatment-effect evidence for Danshen in acute myocardial infarction. Product information is available from QSevidence. This article discusses research methods and evidence organization; experimental, analytical and clinical applications require relevant professional review.